Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF.

Abstract

If tuberculosis (TB) is to be eliminated as a global health problem in the foreseeable future, improved detection of patients, earlier diagnosis and timely identification of rifampicin resistance will be critical. New diagnostics released in recent years have improved this perspective but they require investments in laboratory infrastructure, biosafety and staff specialisation beyond the means of many resource-constrained settings where most patients live. Xpert MTB/RIF, a new assay employing automated nucleic acid amplification to detect Mycobacterium tuberculosis, as well as mutations that confer rifampicin resistance, holds the promise to largely overcome these operational challenges. In this article we position Xpert MTB/RIF in today's TB diagnostic landscape and describe its additional potential as an adjunct to surveillance and surveys, taking into account considerations of pricing and ethics. In what could serve as a model for the future formulation of new policy on diagnostics, we trace the unique process by which the World Health Organization consulted international expertise and systematically assessed published evidence and freshly emerging experience from the field ahead of its endorsement of the Xpert MTB/RIF technology in 2010, summarise subsequent research findings and guidance on who to test and how, and provide perspectives on scaling up the new technology.

• Authors: Karin Weyer, Fuad Mirzayev, Giovanni Battista Migliori, Wayne Van Gemert, Lia D'Ambrosio, Matteo Zignol, Katherine Floyd, Rosella Centis, Daniela M Cirillo, Enrico Tortoli, Chris Gilpin, Jean de Dieu Iragena, Dennis Falzon, Mario Raviglione
• Journal: The European respiratory journal (Eur Respir J) Vol. 42 Issue 1 Pg. 252-71 (Jul 2013) ISSN: 1399-3003 [Electronic] England
• PMID: 23180585 (Publication Type: Journal Article, Review)

Topics

• Cost-Benefit Analysis
• Drug Resistance
• Health Policy
• Humans
• Molecular Diagnostic Techniques (economics, methods)
• Mycobacterium tuberculosis (genetics)
• Nucleic Acid Amplification Techniques
• Polymerase Chain Reaction
• Predictive Value of Tests
• Prevalence
• Reproducibility of Results
• Sputum (microbiology)
• Tuberculosis, Multidrug-Resistant (diagnosis, microbiology)
• Tuberculosis, Pulmonary (diagnosis, microbiology)
• World Health Organization